New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 10, 2014
11:42 EDTGILD, GSK, RHHBYReport claims Tamiflu, Relenza do little to prevent the spread of flu
The Cochrane Collaboration, an independent nonprofit organization that aims to help health professionals, patients, and policy makers access evidence-based medicine to guide their decisions, concluded in a newly published report that neuraminidase inhibitors Tamiflu and Relenza are stockpiled and recommended by public health agencies but have not been proven to prevent the spread of flu or reduce dangerous complications. Tamiflu was co-developed by and is marketed by Gilead Sciences (GILD) and Roche (RHHBY), while Relenza is marketed by GlaxoSmithKline (GSK). Roche said "we disagree with the overall conclusions" and warned they could "potentially have serious public health implications," according to a company statement quoted by BBC News. Reference Link
News For GILD;RHHBY;GSK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 >>
February 2, 2016
16:03 EDTGILDGilead reports Q4 other product sales $523M
Subscribe for More Information
16:02 EDTGILDGilead reports Q4 antiviral product sales increased to $7.9B
Antiviral product sales, which include products in our HIV and liver diseases areas, were $7.9B for the fourth quarter of 2015 compared to $6.7B for the fourth quarter of 2014 primarily as a result of the launch of our HCV products in Japan and continued launches of our HCV products across Europe, partially offset by lower sales of HCV products in the U.S. For 2015, antiviral product sales were $30.2B compared to $22.8B in 2014 primarily due to sales of Harvoni, partially offset by a decrease in sales of Sovaldi.
16:01 EDTGILDGilead reports Q4 total product sales $8.4B
Total product sales for the fourth quarter of 2015 were $8.4B compared to $7.2B for the fourth quarter of 2014. In the fourth quarter of 2015, product sales in the U.S. were $4.8B compared to $5.5B in the fourth quarter of 2014. In Europe, product sales were $1.7B compared to $1.4B in the fourth quarter of 2014. Sales in other international locations increased to $1.9B compared to $373M in the fourth quarter of 2014, primarily due to sales of Sovaldi(R) (sofosbuvir 400 mg) and Harvoni(R) (ledipasvir 90 mg/sofosbuvir 400 mg) in Japan.
16:00 EDTGILDGilead reports Q4 adjusted EPS $3.32, consensus $3.00
Subscribe for More Information
15:12 EDTRHHBYRoche approached Pacific Biosciences about possible acquisition, Reuters says
Subscribe for More Information
15:10 EDTRHHBYRoche approached Pacific Biosciences about possible acquisition, Reuters says
14:32 EDTGILDNotable companies reporting after market close
Subscribe for More Information
12:33 EDTGILDGilead February weekly 83 straddle priced for 6% movement into Q4
11:52 EDTGILDGilead technical notes before earnings news
There is an active bearish head and shoulders pattern on the daily chart that became active when price broke below $93. Downside potential for the pattern, if it remains active and completes, is to the $65 to $62.50 area over time. If the news is bearish, the pattern is likely to continue to develop. If the news is a bullish surprise, it is possible that the pattern will become inactive if price can rise above $93. To void the pattern entirely would take a move above $110.
09:46 EDTGILDIntercept rumored to draw interest from many suitors, Daily Mail says
Subscribe for More Information
08:36 EDTRHHBYPiper Jaffray biopharma analyst holds an analyst/industry conference call
Subscribe for More Information
08:17 EDTGSKAdaptimmune, GSK expand strategic immunotherapy collaboration
Adaptimmune Therapeutics (ADAP) and GlaxoSmithKline (GSK) announced that the companies have expanded the terms of their strategic collaboration agreement to accelerate Adaptimmune's lead clinical cancer program, an affinity enhanced T-cell immunotherapy targeting NY-ESO-1, toward pivotal trials in synovial sarcoma. Adaptimmune and GSK announced a strategic collaboration and licensing agreement in June 2014 for up to five programs, including the lead NY-ESO TCR program. GSK has an option on the NY-ESO-1 program through clinical proof of concept and, on exercise, will assume full responsibility for the program.
07:42 EDTGSKPressure mounts on big pharma names to shrink, sharpen focus, FT says
Subscribe for More Information
06:32 EDTGSKGSK, J&J back Index Ventures' $1B biotech business spinoff, Reuters says
GlaxoSmithKline (GSK) and Johnson & Johnson (JNJ) will back a new spinoff from Index Ventures, which is spinning off its biotech portfolio into a new $1B entity, Reuters reports. The New Medicxi Ventures business will be helmed by the existing life sciences team from Index and will include all the current biotech portfolio firms, the report says. Medicxi raises $229M for a new fund in Europe with GSK and J&J each putting in 25%, Reuters reports. Reference Link
February 1, 2016
11:02 EDTRHHBYRoche: Updated cervical cancer screening guidelines support use of cobas test
Roche announced that recently updated cervical cancer screening guidelines from the American College of Obstetricians and Gynecologists support the use of its cobas HPV Test for primary cervical cancer screening as an alternative to current cytology-based cancer screening methods in women 25 and older. The College's revised Practice Bulletin 157, published in the January issue of Obstetrics & Gynecology, reinforces similar guidance issued in 2015 by the Society for Gynecologic Oncology and the American Society for Colposcopy and Cervical Pathology. The cobas HPV Test was approved by the FDA in 2011 for use in screening women 21 and older with unclear Pap test results and for co-testing with a Pap test in women 30 and older. The FDA approved it for first-line primary cervical cancer screening for women 25 and older in April 2014 following a unanimous recommendation from the independent Microbiology Devices Panel of the FDA's Medical Devices Advisory Committee. Currently utilized by more than 250 labs in the U.S., the cobas HPV Test is the only test approved in the U.S. for all three HPV testing options now supported by three major medical societies.
09:36 EDTGILDActive equity options trading on open
Active equity options trading on open: BAC AAPL FB AMZN TWTR MGM MCD NFLX GILD INTC TSLA AA BABA C
09:23 EDTGILDGilead volatility elevated into Q4 and outlook
Gilead February weekly call option implied volatility is at 62, February is at 44, March is at 38; compared to its 52-week range of 22 to 49, suggesting large near term price movement into the expected release of Q4 results on February 2.
09:05 EDTGILDGilead says EMA validates Type II variation application for Truvada
Subscribe for More Information
05:17 EDTGILDStocks with implied volatility movement; GILD PBR
Subscribe for More Information
January 31, 2016
16:13 EDTRHHBYGenentech receives orphan designation for Avastin in mesothelioma
Subscribe for More Information
1 | 2 | 3 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use